MedTrace Logo

Real-life Study of How to Intensify Treatment With Xolair (OMALIZUMAB) in Chronic Spontaneous Urticaria

NCT04583475 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 163

Last updated 2025-12-23

No results posted yet for this study

Summary

This is an observational study whose main objective is to estimate the frequency of patients benefiting from an intensification of AOM treatment at 3 months.

Conditions

  • Spontaneous Urticaria, Chronic

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Delphine Staumont-Salle, MD,PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-25
Primary Completion
2023-06-22
Completion
2023-06-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04583475 on ClinicalTrials.gov